Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin‐2 and hypoxia‐induced factor‐1a

Abstract: Background: Hepatocellular carcinoma (HCC) is a hypervascular tumor and angiogenesis plays an important role in its progression. Angiogenesis is regulated by a balance between pro and antiangiogenic molecules. The aim of this study was to investigate the expressions of angiogenic factors and elucidate their roles in angiogenesis in HCC.

[1]  S. Thorgeirsson,et al.  Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling , 2004, Hepatology.

[2]  Hideyuki Sakurai,et al.  Pretreatment evaluation of combined HIF‐1α, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer , 2004, International journal of cancer.

[3]  S. Cheung,et al.  Clinical Significance of Thrombospondin 1 Expression in Hepatocellular Carcinoma , 2004, Clinical Cancer Research.

[4]  E. Taniguchi,et al.  Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. , 2004, Journal of hepatology.

[5]  K. Chayama,et al.  Clinical significance of angiopoietin-2 expression at the deepest invasive tumor site of advanced colorectal carcinoma. , 2004, International journal of oncology.

[6]  M. Monden,et al.  Hepatic expression of ANG2 RNA in metastatic colorectal cancer , 2004, Hepatology.

[7]  M. Tsuneyoshi,et al.  Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma , 2003, Journal of clinical pathology.

[8]  S. Fan,et al.  Clinical Significance of Angiogenesis in Gastrointestinal Cancers: A Target for Novel Prognostic and Therapeutic Approaches , 2003, Annals of surgery.

[9]  L. Ellis,et al.  Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. , 2003, Cancer research.

[10]  H. Yu,et al.  Overexpression of VEGF and Angiopoietin 2: A Key to High Vascularity of Hepatocellular Carcinoma? , 2003, Modern Pathology.

[11]  M. Miyazaki,et al.  Angiopoietins and Tie‐2 expression in angiogenesis and proliferation of human hepatocellular carcinoma , 2003, Hepatology.

[12]  P. Sismondi,et al.  Angiopoietin‐2 expression in breast cancer correlates with lymph node invasion and short survival , 2003, International journal of cancer.

[13]  H. Wada,et al.  Expression of angiopoietins and its clinical significance in non-small cell lung cancer. , 2002, Cancer research.

[14]  M. Teh,et al.  Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. , 2002, Experimental cell research.

[15]  J. Kurebayashi,et al.  Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  J. Bruix,et al.  Prognostic prediction and treatment strategy in hepatocellular carcinoma , 2002, Hepatology.

[17]  M. Schindl,et al.  Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  G. Semenza,et al.  Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. , 2001, Cancer research.

[19]  S. Kitano,et al.  Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. , 2001, Cancer research.

[20]  L. Ellis,et al.  The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. , 2001, Cancer research.

[21]  P. Malfertheiner,et al.  Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density , 2001, Virchows Archiv.

[22]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[23]  D. Hicklin,et al.  Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. , 2000, Oncology reports.

[24]  A. Eggert,et al.  High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  L. Ellis,et al.  Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. , 2000, The oncologist.

[26]  Napoleone Ferrara,et al.  Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.

[27]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[28]  D. Mooney,et al.  Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. , 1999, The American journal of pathology.

[29]  G. Garcı́a-Cardeña,et al.  Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[30]  Keizo Sugimachi,et al.  Enhanced expression of thrombospondin‐1 and hypovascularity in human cholangiocarcinoma , 1998, Hepatology.

[31]  J. Isner,et al.  Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. , 1998, Circulation research.

[32]  L. Huang,et al.  Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway , 1998 .

[33]  M. Kojiro,et al.  Expression of vascular endothelial growth factor in human hepatocellular carcinoma , 1998, Hepatology.

[34]  T. Nabika,et al.  Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver , 1998, Hepatology.

[35]  O. Volpert,et al.  A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Y. Yamashita,et al.  Plasma thrombospondin levels in patients with colorectal carcinoma , 1998, Cancer.

[37]  J. Caro,et al.  Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. , 1997, The Journal of biological chemistry.

[38]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[39]  S. Groshen,et al.  Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. , 1997, Journal of the National Cancer Institute.

[40]  Pamela F. Jones,et al.  Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.

[41]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[42]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[43]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Iruela-Arispe,et al.  Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[45]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[46]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[47]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[48]  S. Arii,et al.  Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance. , 2004, Journal of hepatology.

[49]  T. Utsunomiya.  Increased Expression of COX-2 in Nontumor Liver Tissue Is Associated with Shorter Disease-free Survival in Patients with Hepatocellular Carcinoma , 2000 .

[50]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.